Leerink analyst Jeffrey La Rosa initiated coverage of Senti Bio (SNTI) with an Outperform rating and $6 price target The firm believes Senti’s novel LogicGated gene circuit platform offers a promising solution to solve the therapeutic window problem that has plagued cell therapies pursuing cancers with “dirty” antigen targets. The company’s lead clinical candidate, SENTI-202, is an elegantly designed allogeneic, or off-the-shelf, CAR-NK cell therapy in Phase 1 for relapsed or refractory acute myeloid leukemia. For Leerink, the preliminary Phase 1 dose escalation data reported to date help validate SENTI-202’s Logic-Gated design and support a potentially differentiated clinical profile relative to currently available AML therapies and the industry’s past attempts at developing immune cell-based therapies for the indication.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNTI:
- Promising Outlook for Senti Biosciences’ SENTI-202: Positive Phase 1 Results and Innovative CAR-NK Technology Justify Buy Rating
- Senti Biosciences Reports Q3 2025 Financial Results
- Senti Bio reports Q3 EPS (69c), consensus (57c)
- SNTI Upcoming Earnings Report: What to Expect?
- Senti Biosciences’ Innovative CAR NK Cell Therapy Study: A Potential Game-Changer in Blood Cancer Treatment